IP Verse

Ucb competitive analysis

Latest oppositions filed by Ucb

Explore patent oppositions filed by Ucb against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP2784084
Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofGENENTECHApr 23, 2020
EP2531218
Immunoglobulin PreparationCSL BEHRINGSep 11, 2019
EP2282758
Antibodies And Vaccines For Use In Therapeutic And Diagnostic Methods For Alpha-Synuclein-Related DisordersBIOARCTICAug 21, 2019
EP2144613
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABDec 21, 2018
EP2606142
Method For Inactivating Proteases By Ph Change In A Liquid Obtained From A Cell CultureBOEHRINGER INGELHEIMNov 28, 2018
EP2586788
Prevention Of Disulfide Bond Reduction During Recombinant Production Of PolypeptidesGENENTECHAug 29, 2018
EP2794652
Rapid Method For Cloning And Expression Of Cognate Antibody Variable Region Gene SegmentsF HOFFMANN LA ROCHEAug 15, 2018
EP2021463
Culture Method For Obtaining A Clonal Population Of Antigen-Specific B CellsALDER BIOPHARMACEUTICALSAug 23, 2017
EP1478931
Binding Of Pathological Forms Of Prion ProteinsMICROSENS BIOPHAGESep 30, 2016

Latest patents of Ucb opposed by its competitors

Explore Ucb's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3655420
Nov 12, 2025Chromatography1
EP2298800
Mar 27, 2024Sclerostin Binding Antibodies1
EP3630946
Mar 27, 2024Cell Culture Methods6
EP3980047
Feb 14, 2024Inflammatory Disease Treatment With Complement Inhibitors2
EP2301961
Dec 13, 2023Sclerostin Epitopes1
EP3717631
Aug 30, 2023Cell Culture Methods2
EP2251351
Jul 26, 2023Sclerostin Epitopes1
EP3145504
Jul 26, 2023Transdermal Delivery System Including An Interface Mediator1
EP2869844
Jun 21, 2023Treatment For Bone Diseases1
EP2295448
May 31, 2023Sclerostin Epitopes1

Latest PTAB cases involving Ucb

Discover the latest PTAB cases involving Ucb, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 16, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Ucb

IPR2019-01480Aug 12, 2019UCBMASTERNAKTerminated-Settled
IPR2019-01480Aug 12, 2019UCBNOVIMMUNETerminated-Settled
IPR2019-01481Aug 12, 2019UCBMASTERNAKTerminated-Settled
IPR2019-01481Aug 12, 2019UCBNOVIMMUNETerminated-Settled
PGR2019-00044Apr 1, 2019UCBGENENTECHTerminated
IPR2019-00400Dec 13, 2018APOTEXUCB BIOPHARMAFinal Written Decision
IPR2016-01596Aug 22, 2016ALEMBIC PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01596Aug 22, 2016ALEMBIC PHARMACEUTICALSUCB PHARMA S.A.Final Written Decision
IPR2016-01665Aug 22, 2016AMERIGEN PHARMACEUTICALSUCB PHARMAFinal Written Decision
IPR2016-01665Aug 22, 2016AMERIGEN PHARMACEUTICALSUCB PHARMA S.A.Final Written Decision

Peer Comparison New

IP litigation analysis comparing Ucb with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
UCB BIOPHARMA SPRL56 - -
AMW62 - -
BIOCON RESEARCH - 8 - -
KYOWA HAKKO KIRIN - 16 - 3